# Kereos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kereos

- Industry: Pharmaceuticals
- Headquarters: Missouri City, US
- Website: www.kereos.com
- Total disclosed funding: $20M
- Latest round: Series B (Sep 20, 2005)
- Investors on record: 13

## About

Kereos, Inc. specializes in the sale of premium domain names, enabling businesses and individuals to establish an online presence. The company focuses on facilitating brand identity and enhancing digital communication through its offerings.Kereos, Inc. was founded in 1999 in Missouri City, US, and operates primarily in the domain name market. The company has successfully raised a total of USD 1.13 mn in funding through 7 deals, with the most recent financing occurring in January 2012. The founder, Mustafa Saatcioglu, has a history of involvement in the tech industry, contributing to Kereos' development in the domain space.Kereos.com offers a domain name for sale, specifically targeting businesses and individuals seeking to establish an online presence. The core offering is the domain name itself, which serves as a web address that allows users to create websites, host content, and engage with customers online. Its functionality is rooted in enabling brand identity, facilitating e-commerce, and enhancing digital communication. The company primarily serves a diverse customer base that includes entrepreneurs, startups, and established businesses looking to expand their digital footprint. Key markets for these domain services extend globally, encompassing regions such as North America, Europe, and Asia, where there is a growing demand for digital real estate as businesses increasingly shift to online platforms.Revenue generation for Kereos.com is based on the sale of domain names, with a specific pricing structure established for potential buyers. The flagship offering is the domain KerEos.com, priced at USD 595 or available through a payment plan of USD 24.79 per month for 24 months. This model supports both one-time purchases and recurring payments, enhancing customer convenience while driving consistent revenue streams. The focus on domain sales aligns with the increasing trend of digital business expansion, allowing clients to leverage unique web addresses for branding and operational needs.Kereos plans to use the financing raised in January 2012 to enhance its product offerings and expand its market reach. Upcoming products may include additional premium domain names aimed at niche markets. The company aims to target new geographic markets, particularly in Asia and Europe, by the end of 2023 to capitalize on the rising demand for digital identity solutions.

## Funding rounds

- Series B, Sep 20, 2005, $20M — Charter Life Sciences, RiverVest Ventures Partners, Apjohn Ventures, Triathlon Medical Partners, Vectis Capital, Orchard Venture Partners, Prolog Ventures, MB Venture Partners, Alafi Capital, 180 Degree Capital, Lux Capital, Koninklijke Philips N.V., Genentech, Inc.
- Seed, Jan 1, 2001, $0.3M — RiverVest Ventures Partners

## Investors

- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Seed, Series B
- Charter Life Sciences (https://capitalatlas.ai/funds/charter-life-sciences) — Series B
- Apjohn Ventures (https://capitalatlas.ai/funds/apjohn-ventures) — Series B
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series B
- Vectis Capital (https://capitalatlas.ai/funds/vectis-capital) — Series B
- Orchard Venture Partners (https://capitalatlas.ai/funds/orchard-venture-partners) — Series B
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series B
- MB Venture Partners (https://capitalatlas.ai/funds/mb-venture-partners) — Series B
- Alafi Capital (https://capitalatlas.ai/funds/alafi-capital) — Series B
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series B
- Koninklijke Philips N.V. — Series B
- Genentech, Inc. — Series B